Anti-PD-1 antibodies

US12312405B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• David A. Blair · Sandy Hook, US
• Nicole K. Garaffa · Trumbull, US
• Pankaj Gupta · Scarsdale, US
• Priyanka GUPTA · Danbury, US
• Fei HAN · Sandy Hook, US
• Aaron Timothy Karlak · Beacon Falls, US
• Dongmei LIU · Oxford, US
• Mouhamadou L. Mbow · King of Prussia, US
• Joseph A. Mozdzierz · Mahopac, US
• Kerry-Leigh RALPH · Bethel, US
• Abdulsalam SHAABAN · Ridgefield, US
• Helen Haixia Wu · Danbury, US
• Guangwei Yang · Cheshire, US

Key dates

• Filing date: May 24, 2021
• Grant date: May 27, 2025
• Expiry date: Jun 7, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to new anti-PD-1 (Programmed cell death 1) antibodies and antigen-binding fragments thereof for therapeutic and diagnostic methods and compositions using them.